Targeted Oncology

Phase 3 TROPION-Lung17 Trial Initiates TROP2-Directed Therapy in NSCLC

TROPION-Lung17 will enroll approximately 400 patients across global sites. Participants are randomized 1:1 to receive either ...
CURE

Large Cell Lung Cancer Overview: What Patients Need to Know

Large cell carcinoma is aggressive, requiring early detection through imaging and biopsy for optimal treatment outcomes.

For Lung Cancer Patients, Shame Is a Deadly Side Effect

Shame can shape how early patients get diagnosed, and how aggressively they pursue treatment, if at all. In a 2014 study, Dr.

Antibody therapy shrinks immunotherapy-resistant lung cancer tumors in mice

An investigational therapy significantly shrank lung cancer tumors that are notoriously resistant to treatment by encouraging ...
American Lung Association

Double Risk: How Radon and Smoking Fuel Lung Cancer

Radon and smoking are both known causes of lung cancer, but when someone is exposed to both, the results can be deadly.
Nasdaq

Novel Computational Pathology-Based TROP2 Biomarker for Datopotamab Deruxtecan Was Predictive of Clinical Outcomes in Patients with Non-Small Cell Lung Cancer in TROPION-Lung01 ...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)-- Results from an exploratory analysis of the TROPION-Lung01 phase 3 trial showed TROP2 as measured by quantitative continuous scoring (QCS), AstraZeneca’s ...